BioLife SolutionsBLFS
BLFS
About: BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Employees: 159
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
58% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 19
4% more funds holding
Funds holding: 180 [Q4 2024] → 188 (+8) [Q1 2025]
1.58% more ownership
Funds ownership: 100.89% [Q4 2024] → 102.48% (+1.58%) [Q1 2025]
3% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 61
7% less capital invested
Capital invested by funds: $1.21B [Q4 2024] → $1.13B (-$89.9M) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
98% less call options, than puts
Call options by funds: $65K | Put options by funds: $4.17M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
36%
upside
Avg. target
$30
36%
upside
High target
$30
36%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 36%upside $30 | Buy Reiterated | 13 May 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72%
The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
PRNewsWire
1 month ago
BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025
BOTHELL, Wash. , May 14, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the company will be participating in the following investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025 Minneapolis, MN at the Renaissance Hotel Benchmark 2025 Healthcare House Call Virtual Conference May 29, 2025 Virtual Jefferies Global Life Sciences Conference June 3 – 5, 2025 New York, NY at the Marriott Marquis Wolfe Research Small & Mid-Cap Conference June 5, 2025 New York, NY at Wolfe Headquarters Northland Growth Conference 2025 June 25, 2025 Virtual About BioLife Solutions BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Positive
Zacks Investment Research
1 month ago
Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Seeking Alpha
1 month ago
BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - Chairman and Chief Executive Officer Conference Call Participants Matthew Stanton - Jefferies Paul Knight - KeyBanc Chad Wiatrowski - TD Cowen Thomas Flaten - Lake Street Matthew Hewitt - Craig-Hallum Capital Group Carl Byrnes - Northland Capital Markets Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for standing by.
Positive
Zacks Investment Research
1 month ago
BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year ago.
Neutral
PRNewsWire
1 month ago
BioLife Solutions Updates Earnings Call Information
BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET.
Neutral
PRNewsWire
1 month ago
BioLife Solutions Reports First Quarter 2025 Financial Results
Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
Positive
Seeking Alpha
1 month ago
Stock Picks From Seeking Alpha's April 2025 New Analysts
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside.
Neutral
PRNewsWire
1 month ago
BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
BOTHELL, Wash. , April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025.
Neutral
PRNewsWire
2 months ago
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash. , April 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology.
Charts implemented using Lightweight Charts™